The International Society for Cell and Gene Therapy has created a group to tackle the rising number of commercial cell bank services that are misleading patients. The International Society for Cell and Gene Therapy (ISCT) has announced the formation of a global consortium to combat the growing number of unproven commercial cell banking services. The group will
UNC Lineberger’s Timothy Gerson, MD, PhD, and colleagues have identified a potential approach to stop the growth of the most common type of brain tumor in children. Their research was published in the journal Development. UNC Lineberger’s Timothy Gerson, MD, PhD and colleagues reported in the journal Development that by blocking a signal called GSK-3, they could control tumor
“The Italian government has decided to invest 60 million euros on CAR-T therapies, 10 million for each of the 6 pharmaceutical workshops”. This was stated by Health Minister Roberto Speranza, explaining to the joint committees of the Senate and the House the program lines of his department. CAR-T cell therapy consists of genetic manipulation of
The announcement by the Health Minister Speranza: “60 million to 6 workshops to produce Car-T against cancer” The Car-t therapies are “a strategic segment on which the government has decided to invest 60 million euros, foreseeing 10 million for each pharmaceutical workshop”, or high-tech laboratories in which the patient’s immune cells against tumors are modified.
Researchers from Stowers Institute for Medical Research in Kansas City, MO have identified proteins that are involved in tumor growth and metastasis in many cancers such as breast cancer. The research was published in Science Advances on October 23. Breast cancer is one of the many types of cancer that can be caused by gene alterations of
Helper T cells appear vital to more robust anti-tumor response Cancer immunotherapy drugs trigger the body’s immune system to attack tumors and have revolutionized the treatment of certain cancers, such as lymphoma, lung cancer and melanoma. Yet, while some patients respond well to the drugs, others don’t respond at all. Cancer immunologists want to change
Gene editing to correct genetic faults and removing the risk of hereditary diseases may soon become reality. Researchers have come up with a new gene editing technology that could help patients with sickle cell anaemia and up 89 percent of other genetic defects. This new technique is called the “prime editing” and is being developed
Unmatched Scope of Resources Will Identify Distinctive Disease Mechanisms in Small Patient Subgroups, Supporting Development of Custom Therapeutic Approaches Source NYSCF Bloomberg Philanthropies, Johns Hopkins University School of Medicine (JHUSOM), and The New York Stem Cell Foundation (NYSCF) Research Institute today announced an initiative to fundamentally advance and expand the science of precision medicine, in
Source NIH Initial investment aims to advance accessible and scalable candidate interventions into clinical trials within 10 years. The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease (SCD) and HIV. The Bill & Melinda Gates
Treatment approved for approximately 90% of patients with cystic fibrosis, many of whom had no approved therapeutic options Source FDA The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Trikafta is approved for patients 12 years and older
